316 related articles for article (PubMed ID: 31182754)
1. Targeting CLDN18.2 by CD3 Bispecific and ADC Modalities for the Treatments of Gastric and Pancreatic Cancer.
Zhu G; Foletti D; Liu X; Ding S; Melton Witt J; Hasa-Moreno A; Rickert M; Holz C; Aschenbrenner L; Yang AH; Kraynov E; Evering W; Obert L; Lee C; Sai T; Mistry T; Lindquist KC; Van Blarcom T; Strop P; Chaparro-Riggers J; Liu SH
Sci Rep; 2019 Jun; 9(1):8420. PubMed ID: 31182754
[TBL] [Abstract][Full Text] [Related]
2. Preclinical characterization of a Fab-like CD3/CLDN18.2 XFab® bispecific antibody against solid tumors.
Xu G; Qian N; Liu Y; Li H; Yang C; Wang J; Wang F; Chen L; Bai G; Xu Q; Pan X; Gao X
Immunobiology; 2022 Nov; 227(6):152283. PubMed ID: 36198215
[TBL] [Abstract][Full Text] [Related]
3. Preclinical Efficacy and Safety Comparison of CD3 Bispecific and ADC Modalities Targeting BCMA for the Treatment of Multiple Myeloma.
Panowski SH; Kuo TC; Zhang Y; Chen A; Geng T; Aschenbrenner L; Kamperschroer C; Pascua E; Chen W; Delaria K; Farias S; Bateman M; Dushin RG; Chin SM; Van Blarcom TJ; Yeung YA; Lindquist KC; Chunyk AG; Kuang B; Han B; Mirsky M; Pardo I; Buetow B; Martin TG; Wolf JL; Shelton D; Rajpal A; Strop P; Chaparro-Riggers J; Sasu BJ
Mol Cancer Ther; 2019 Nov; 18(11):2008-2020. PubMed ID: 31434693
[TBL] [Abstract][Full Text] [Related]
4. Claudin18.2-Specific Chimeric Antigen Receptor Engineered T Cells for the Treatment of Gastric Cancer.
Jiang H; Shi Z; Wang P; Wang C; Yang L; Du G; Zhang H; Shi B; Jia J; Li Q; Wang H; Li Z
J Natl Cancer Inst; 2019 Apr; 111(4):409-418. PubMed ID: 30203099
[TBL] [Abstract][Full Text] [Related]
5. Development of a Novel CLDN18.2-directed Monoclonal Antibody and Antibody-Drug Conjugate for Treatment of CLDN18.2-Positive Cancers.
O'Brien NA; McDermott MSJ; Zhang J; Gong KW; Lu M; Hoffstrom B; Luo T; Ayala R; Chau K; Liang M; Madrid AM; Donahue TR; Glaspy JA; Presta L; Slamon DJ
Mol Cancer Ther; 2023 Dec; 22(12):1365-1375. PubMed ID: 37788341
[TBL] [Abstract][Full Text] [Related]
6. DR30318, a novel tri-specific T cell engager for Claudin 18.2 positive cancers immunotherapy.
Ma Z; Zhou Z; Duan W; Yao G; Sheng S; Zong S; Zhang X; Li C; Liu Y; Ou F; Dahar MR; Huang Y; Yu L
Cancer Immunol Immunother; 2024 Mar; 73(5):82. PubMed ID: 38554200
[TBL] [Abstract][Full Text] [Related]
7. Safety and Pharmacokinetic Assessment of the FIC CLDN18.2/4-1BB Bispecific Antibody in Rhesus Monkeys.
Wang J; Dong T; Gong X; Li D; Sun J; Luo Y; Wu H
Int J Toxicol; 2024; 43(3):291-300. PubMed ID: 38115178
[TBL] [Abstract][Full Text] [Related]
8. CLDN18.2 and 4-1BB bispecific antibody givastomig exerts antitumor activity through CLDN18.2-expressing tumor-directed T-cell activation.
Gao J; Wang Z; Jiang W; Zhang Y; Meng Z; Niu Y; Sheng Z; Chen C; Liu X; Chen X; Liu C; Jia K; Zhang C; Liao H; Jung J; Sung E; Chung H; Zhang JZ; Zhu AX; Shen L
J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37364935
[TBL] [Abstract][Full Text] [Related]
9. CLDN18.2 BiTE Engages Effector and Regulatory T Cells for Antitumor Immune Response in Preclinical Models of Pancreatic Cancer.
Xu Y; Fu J; Henderson M; Lee F; Jurcak N; Henn A; Wahl J; Shao Y; Wang J; Lyman M; Funes V; Espinoza B; Zhang R; Washington I; Chen SY; Zlomke H; Wang J; Niu N; Li P; Meng F; Burns W; Friedrich M; Stienen S; Bailis JM; Zheng L
Gastroenterology; 2023 Nov; 165(5):1219-1232. PubMed ID: 37507075
[TBL] [Abstract][Full Text] [Related]
10. Development of a Humanized VHH Based Recombinant Antibody Targeting Claudin 18.2 Positive Cancers.
Zhong W; Lu Y; Ma Z; He Y; Ding Y; Yao G; Zhou Z; Dong J; Fang Y; Jiang W; Wang W; Huang Y
Front Immunol; 2022; 13():885424. PubMed ID: 35837391
[TBL] [Abstract][Full Text] [Related]
11. An auristatin-based antibody-drug conjugate targeting HER3 enhances the radiation response in pancreatic cancer.
Bourillon L; Bourgier C; Gaborit N; Garambois V; Llès E; Zampieri A; Ogier C; Jarlier M; Radosevic-Robin N; Orsetti B; Delpech H; Theillet C; Colombo PE; Azria D; Pèlegrin A; Larbouret C; Chardès T
Int J Cancer; 2019 Oct; 145(7):1838-1851. PubMed ID: 30882895
[TBL] [Abstract][Full Text] [Related]
12. Intracerebral bispecific ligand-antibody conjugate increases survival of animals bearing endogenously arising brain tumors.
Patrick TA; Kranz DM; Zachary JF; Roy EJ
Int J Cancer; 1998 Nov; 78(4):470-9. PubMed ID: 9797136
[TBL] [Abstract][Full Text] [Related]
13. A bispecific antibody targeting HER2 and CLDN18.2 eliminates gastric cancer cells expressing dual antigens by enhancing the immune effector function.
Yue J; Shao S; Zhou J; Luo W; Xu Y; Zhang Q; Jiang J; Zhu MM
Invest New Drugs; 2024 Feb; 42(1):106-115. PubMed ID: 38198061
[TBL] [Abstract][Full Text] [Related]
14. Internal enhancement of DNA damage by a novel bispecific antibody-drug conjugate-like therapeutics via blockage of mTOR and PD-L1 signal pathways in pancreatic cancer.
Cao R; Song W; Ye C; Liu X; Li L; Li Y; Yao H; Zhou X; Li L; Shao R
Cancer Med; 2019 Feb; 8(2):643-655. PubMed ID: 30681288
[TBL] [Abstract][Full Text] [Related]
15. Claudin 18.2 is a target for IMAB362 antibody in pancreatic neoplasms.
Wöll S; Schlitter AM; Dhaene K; Roller M; Esposito I; Sahin U; Türeci Ö
Int J Cancer; 2014 Feb; 134(3):731-9. PubMed ID: 23900716
[TBL] [Abstract][Full Text] [Related]
16. Effective targeting of prostate cancer by lymphocytes redirected by a PSMA × CD3 bispecific single-chain diabody.
Fortmüller K; Alt K; Gierschner D; Wolf P; Baum V; Freudenberg N; Wetterauer U; Elsässer-Beile U; Bühler P
Prostate; 2011 May; 71(6):588-96. PubMed ID: 20945402
[TBL] [Abstract][Full Text] [Related]
17. Transcriptional regulation of claudin-18 via specific protein kinase C signaling pathways and modification of DNA methylation in human pancreatic cancer cells.
Ito T; Kojima T; Yamaguchi H; Kyuno D; Kimura Y; Imamura M; Takasawa A; Murata M; Tanaka S; Hirata K; Sawada N
J Cell Biochem; 2011 Jul; 112(7):1761-72. PubMed ID: 21381080
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic efficacy, pharmacokinetic profiles, and toxicological activities of humanized antibody-drug conjugate Zt/g4-MMAE targeting RON receptor tyrosine kinase for cancer therapy.
Yao HP; Feng L; Suthe SR; Chen LH; Weng TH; Hu CY; Jun ES; Wu ZG; Wang WL; Kim SC; Tong XM; Wang MH
J Immunother Cancer; 2019 Mar; 7(1):75. PubMed ID: 30871619
[TBL] [Abstract][Full Text] [Related]
19. FAP-targeted CAR-T suppresses MDSCs recruitment to improve the antitumor efficacy of claudin18.2-targeted CAR-T against pancreatic cancer.
Liu Y; Sun Y; Wang P; Li S; Dong Y; Zhou M; Shi B; Jiang H; Sun R; Li Z
J Transl Med; 2023 Apr; 21(1):255. PubMed ID: 37046312
[TBL] [Abstract][Full Text] [Related]
20. Author Correction: Targeting CLDN18.2 by CD3 Bispecific and ADC Modalities for the Treatments of Gastric and Pancreatic Cancer.
Zhu G; Foletti D; Liu X; Ding S; Melton Witt J; Hasa-Moreno A; Rickert M; Holz C; Aschenbrenner L; Yang AH; Kraynov E; Evering W; Obert L; Lee C; Sai T; Mistry T; Lindquist KC; Van Blarcom T; Strop P; Chaparro-Riggers J; Liu SH
Sci Rep; 2019 Nov; 9(1):16735. PubMed ID: 31700121
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
